Saheli Sadanand: Excited to Share a New Cancer Vaccine Study in Nature Medicine
Saheli Sadanand, Deputy Editor of Nature Medicine, shared a post on LinkedIn:
“Excited to share a cool new cancer vaccine study in Nature Medicine!
First, some background:
In 2024, Nature Medicine published the primary results from a phase 1 trial evaluating a lymph node-targeting vaccine in 25 patients with minimal residual mutant KRAS (mKRAS) Pancreatic Cancer or Colorectal Cancer following standard locoregional treatment. Relapse rates for these cancers are high. The vaccine contains two amphiphile mKRAS peptides + amphiphile CpG (as an adjuvant). The vaccine was safe, reduced expression of tumor biomarkers and induced mKRAS-specific T cells.
This week we published final results from this trial.
Key findings and reasons to be excited by these updated data are:
– At a median follow-up of 19.7 months, the magnitude of mKRAS-specific T cell responses was directly correlated with efficacy. 84% of patients made mKRAS-specific T cell responses.
– In the 17 patients with a strong T cell response, median radiographic recurrence-free survival (mRFS) and median overall survival (mOS) were not reached. Conversely, patients with weak T cell responses had a mRFS of 3.02 months and a mOS of 15.98 months.
– In patients with pancreatic cancer, mRFS was 15.31 months and mOS was 28.94 months, exceeding historical control data
– In 67% of patients, there were not only responses to mKRAS peptides included in the vaccine, but also to other mKRAS peptides unique to each patient’s tumor and *not* included in the vaccine (antigen spreading!)
This is an off-the-shelf vaccine that does not need to be individually manufactured for each patient
This vaccine is currently being evaluated in a phase 2 RCT — stay tuned!”
Title: Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results
Authors: Zev A. Wainberg, Colin D. Weekes, Muhammad Furqan, Pashtoon M. Kasi, Craig E. Devoe, Alexis D. Leal, Vincent Chung, James R. Perry, Thian Kheoh, Lisa K. McNeil, Esther Welkowsky, Peter C. DeMuth, Christopher M. Haqq, Shubham Pant, Eileen M. O’Reilly
More posts featuring Saheli Sadanand on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023